Clinical trials: Rectal Hypersensitivity
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Irritable Colon
Sb-705498 Rectal Pain Study
SB-705498 has demonstrated efficacy in several preclinical and human experimental pain models. This study will investigate the efficacy of SB-705498 in patients with rectal pain.
- Trial name
- NCT00461682
- Testing
- SB-705498
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Breast Cancer, Colorectal Cancer
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Colorectal Cancer, Pain
- Trial name
- NCT00305643
- Testing
- Capecitabine, Celecoxib, Radiation Therapy
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Lidocaine for Oxaliplatin-induced Neuropathy
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen.
- Conditions
- Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
- Trial name
- NCT03254394
- Testing
- Lidocaine Hydrochloride, FOLFOX regimen
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine